ALPS Advisors’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
APM
RCM
FFM
VCM
OCA
TCM
ALPS Advisors's DNTH Position: Q1 2026 in Review
ALPS Advisors increased its Dianthus Therapeutics (DNTH) stake by 2.8% in Q1 2026, buying an estimated $57.9K and bringing the position to 36,206 shares worth $3.04M. The position accounts for 0.01% of the portfolio, ranked #331.
ALPS Advisors first reported a position in DNTH in Q2 2019 and has held it in 18 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.
- ALPS Advisors held 36,206 shares of Dianthus Therapeutics worth $3.04M as of Q1 2026.
- ALPS Advisors bought 1,000 Dianthus Therapeutics shares in Q1 2026, an estimated $57.9K.
- Dianthus Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #331 holding.
- ALPS Advisors first reported a position in Dianthus Therapeutics in Q2 2019 and has held it in 18 quarters since.
- 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.
Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.